Search
Influenza A virus A/Singapore/INFIMH-16-0019/2016 NIB-104 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14558ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Maryland/15/2016 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB14595ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14604ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14605ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Texas/50/2012 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB14606ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Wisconsin/1/2010) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14609ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14614ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Influenza B virus B/Colorado/06/2017 live (attenuated) antigen
go.drugbank.com/drugs/DB14697ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019.
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15501ApprovedWithdrawnThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it